SECTM1 and cancer: Further, treatment of CD7-positive cancer cells with K12 CAR-T also triggered robust secretion of IFN-γ (Figure 2H), with a spread in concentration from 6.1–22.5 ng/mL that correlated strongly with CD7 expression on cancer cells (Figure 2I, R2 = 0.859).